Healx has dosed the first subject in the open-label Phase II INSPIRE-NF1 trial to assess the efficacy and safety of HLX-1502 ...

Healx, an AI-enabled, clinical-stage biotech company dedicated to rare diseases, today announced the first patient has been ...

Healx has dosed the first patient in a Phase II trial assessing its lead pipeline candidate HLX-1502 in patients with neurofibromatosis type 1 (NF1), while the FDA approved SpringWorks Therapeutics’ ...

“There are no treatments for many NF1 symptoms; current treatments for NF1 plexiform neurofibromas, such as surgery and MEK inhibitors, are helpful but come with their own set of trade ...

Cambridge biotech Healx stands on the cusp of history after dosing the first patient with a rare and deadly cancer with a ...

Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively ...

Older adults with cancer had a lower risk for Alzheimer’s disease and related dementias than cancer-free individuals of the same age, according to results of a longitudinal retrospective study ...

As the 2025 awards season heats up, one name is making waves in Hollywood: Adam Pearson. His role in the film A Different Man, alongside Sebastian Stan, has not only put him in the spotlight but also ...

STAMFORD, Conn., Feb. 20, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today ...